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Abstract 
Objective: Completion Lymph Node Dissection (CLND) is the current standard of practice for patients with a 
positive Sentinel Lymph Node Biopsy (SLNB). Significant morbidity is associated to CLND, so we tried to 
evaluate which prognostic variables could predict NSLN invasion in SLN-positive patients and their impact 
on the overall survival (OS). 
Methods: A retrospective chart review of 603 patients that had undergone SLNB for melanoma between 
2000 and 2009 at our department was done. 100 SLN were positive at the histopathological analysis of SLN. 
Demographic variables, primary melanoma, SLN pathologic features and results of CLND were analysed. 
Multivariate logistic regression and OS analyses were carried out to test the prognostic relevance of clinico-
pathologic variables on CLND results and disease course. 
Results: Breslow thickness, ulceration and micro/macrometastatic pattern of SLN invasion carried a 
significantly independent higher likelihood of NSLN involvement; Starz classification did not maintain a 
statistical significance in multivariate analysis. Only one patient (4.3%) without adverse prognostic factors 
showed NSLN involvement, which was found in 33.3% of patients with one and 55.9% with two or more 
adverse parameters (p = 0.0001). OS analyses confirmed the prognostic significance of these factors. 
Conclusion: Waiting for the results of Multicenter Selective Lymphadenectomy Trial II, our study suggests a 
clinically useful and easily applicable means of identifying patients with an unfavourable disease course. 
The presence of one or more adverse factors identifies patients in whom CLND is mandatory to include 
thereafter in a more strict follow-up program. Moreover, the finding of no adverse prognostic indicators 
associated to the presence of significant co-morbidities and/or elderly age, could be useful in identifying 
patients not to treat by CLND. 
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Introduction 
Since the introduction of sentinel lymph node biopsy (SLNB) from Morton et al. [1] in early 1990s 
for patients with melanoma, this approach has been established as a diagnostic procedure in melanoma. 
SLNB represents the to-date most accurate staging procedure for the early identification of regional node 
metastases. Micrometastases in sentinel lymph node are prognostically significant in melanoma [2] and 
were therefore included in the revised American Joint Committee on Cancer (AJCC) Classification [3]. The 
finding of a positive SLN identify patients who might benefit from completion lymph node dissection (CLND) 
[4]. However, CLND carries significant morbidity [5] and [6] and there is no consensus on the benefit of a 
completion dissection in melanoma patients. In fact reports in the literature showed that only from 14 to 
28% [7], [8], [9], [10] and [11] of positive patients will harbour further disease in the affected basin. 
Theoretically, only patients with involvement of additional, non-sentinel lymph nodes (NSLN) in the CLND 
specimen should benefit from a CLND. This suggests that a large percentage of patients may undergo an 
unnecessary, morbid procedure for no apparent gain [12], [13], [14], [15] and [16]. Recent efforts have 
been made to identify those patients least likely to have a metastatic disease in the NSLN, who may 
potentially avoid a further surgical operation [17], [18], [19], [20] and [21]. 
The objective of this study was to identify which clinico-pathologic features of primary melanoma 
and SLN are predictive for NSLN involvement and to further ascertain their prognostic role by assessing 
their relationship with the clinical course in terms of OS. 
 
Materials and methods 
Patients, lymphatic mapping, sentinel lymph node biopsy and completion lymphadenectomy 
SLNB was performed in 603 primary melanoma patients in our Department from January 2000 until 
March 2009, the follow-up was extended until December 2009. An SLN involvement was found in 100/603 
patients (16.6%). Patients were enrolled on the basis of guideline criteria [3], [22], [23] and [24]. SLN was 
performed in the presence of melanoma >1 mm, or even lower if ulcerated or Clark IV–V or presence of 
mitoses more than or equal to 1/mm2. SLNB was not performed in patients aged more than 75 years. 
Staging for visceral occult metastases before SLNB was performed according to national Italian guidelines 
[22]. Patients with primary melanoma less than or equal to 2 mm without ulceration underwent chest X 
rays and abdomen ultrasound, whereas patients with deeper Breslow thickness performed brain, lung and 
abdomen computed tomography (CT). At the time of SLNB, there was no clinical or radiological evidence of 
melanoma metastases. 
The SLNs were detected by lymphoscintigraphy and patent blue dye. All radio-labeled lymph nodes 
were considered to be SLN and excised. A median number of 2 sentinel nodes (range: 1–4) were removed. 
SLNs were fixed in formaldehyde and bisected along the long axis of the ilar region [25]. Depending of its 
size, the bisected nodes were embedded in one or more paraffin blocks. Paraplast sections at five intervals 
of 50 μm were prepared from each paraffin block. From each paraplast section, four slides were made and 
stained with conventional histopathology (hematoxylin-eosin) and immuno-hystochemistry (S-100 and 
HMB-45). 
The pattern of SLN involvement was defined as macro- or microscopic on the basis of the presence 
or absence, respectively, of gross extracapsular extension [3]. 
The penetration depth was measured with an ocular micrometer as maximum distance of tumour cells 
from the interior margin of the lymph node capsule, as described by Starz et al. [17]. Presence of tumour 
cells up to 0.3 mm was classified as Starz-I, invasion between 0.3 mm and 1.0 mm was Starz-II, and a 
deeper invasion meant Starz-III. The NSLN were analysed only with H&E. 
Patient’s characteristics included: 1) demographic data (sex, age); 2) histologic features of the 
primary melanoma (Breslow thickness, Clark level, histologic subtype, ulceration); 3) data from the SLN 
included: number of SLN removed, number of positive SLNs, localisation of SLN (head/neck, axilla, inguinal), 
pattern of invasion (micro-/macro-metastases), depth invasion of metastatic cells in the SLN (Starz 
Classification 2004) [17]. The mitotic rate was recorded for all patients but it was not taken into 
consideration for this study purposes in as much as according to the updated AJCC classification [3] was not 
shown to carry a prognostic relevance in the disease outcome of stage III patients. 
 
Statistical analyses 
Statistical analyses were performed using the SPSS 17 Statistical Software. Both parametric and 
non-parametric tests were used; only “p” values of parametric tests were reported, as the results of the 
two tests were similar. Univariate and multivariate logistic regression were used to test for the significance 
of the predictor variables’ association with NSLN metastases. Overall survival (OS) was calculated from the 
surgical excision of SLN to the date of death or last check-up for all patients. Survival estimates were 
derived by the Kaplan–Meier method [26] and the statistical comparison was done by the log-rank test 
[27]. Univariate analyses were carried out to evaluate the prognostic role of different variables. 
 
Results 
Clinico-pathologic variables associated to NSLN involvement 
Patients characteristics with regard to clinical data, primary melanoma, SLN and CLND are given in 
Table 1 according to the presence of NSLN involvement which was detected in 31 out of 100 of patients 
(Table 1). 
Univariate logistic regression showed that the parameters associated with a higher likelihood of 
NSLN involvement were Breslow thickness, ulceration, micro-/macro-metastatic pattern and Starz 
classification. In particular, the odds ratio (OR) was 1.52 for Breslow thickness, 4.59 for ulceration, 6.42 for 
the micro/macro-metastatic pattern and 2.32 for the Starz classification [17] (Table 2). The highest 
percentages of NSLN involvement were found in patients with Breslow thickness >4 mm (52%), ulceration 
(53.6%), macro-metastatic pattern (70%) and grade III Starz classification (40%). On the other hand, NSLN 
involvement after a positive SLN was found in 11.5% of patients with thin primary (between 1 and 2 mm) 
and 5.5% Starz I. 
 
 
Multivariate logistic regression confirmed the independent prognostic role on NSLN involvement 
for Breslow thickness, ulceration and micro-/macrometastatic pattern, whilst Starz classification did not 
maintain a statistical significance. Only one patient (4.3%) without adverse prognostic factors (i.e. Breslow 
thickness ≤2 mm; no ulceration; SLN micro-metastatic pattern) showed NSLN involvement, whilst the 
percentage increased to 33.3% for one adverse indicator and 55.9% for two or more (p = 0.0001, OR 4.4; 
confidence intervals 2.1–9.0). 
 
 
 
  
Overall survival 
The median follow-up is 2.5 years (range: 6 months–9.6 years). Univariate analysis of OS was 
performed for all the parameters reported in Table 1. 
The OS univariate analyses showed that the variables with a statistical prognostic significance were 
the same found to be associated with the higher percentage of NSLN involvement, in particular Breslow 
thickness>2 mm (5-year rate: 87.4% vs 50.8%; p = 0.0069), ulceration (5-year rate: 67.9% vs 41.3%; p = 
0.0495) and SLN micro-/macro-metastatic pattern (63.1% vs 35%; p = 0.0190) ( Fig. 1). 
 
The OS was thereafter calculated on the basis of the presence of no adverse indicators, one, two or 
more. The 5-year survival rate was 84.4% in patients without adverse parameters and 66.6% in patients 
with one adverse factor. A striking reduction in 5-year OS was found in patients with two or more adverse 
indicators (38.3%)(p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Yet considerable effort has been spent in trying to identify which positive SLN patients are likely to 
harbour NSLN metastases. Waiting for the final results of the Multicenter Selective Lymphadenectomy Trial 
(MSLT-II) that will aid to choose the necessary treatment based on different analysed factors, at the 
moment literature evidences are conflicting. In fact, even if several clinico-pathologic characteristics related 
to both primary melanoma (tumour thickness, ulceration, site and histological subtype) and SLN (number of 
positive SLNs, SLN tumour size) have been associated to the NSLN status, the results of different studies 
were controversial and some of them definitely failed to identify any parameter able to predict NSLN 
involvement [8], [9] and [28]. 
             These evidences prompted us to try to identify in our positive SLN patients the most relevant 
parameters for the prediction of NSLN metastatic involvement and to ascertain whether clinico-pathologic 
SLN features correlate to the clinical course in terms of OS. Our aim was to identify variables easy to 
measure and reproducible to combine at the hope to identify clinically useful predictors of NSLN 
involvement and significant on OS. For that reason, we did not include in our analysis the SLN tumour 
burden, even if many studies have found the size of the metastatic deposits in the SLN to be predictive of 
NSLN involvement [7], [9], [10] and [11]. Also recently, Cadili et al. [21] confirmed the prognostic relevance 
of SLN total tumour size on both NSLN involvement and disease course in a large melanoma patient cohort. 
However, there is not agreement on the different features to be considered as predictive for NSLN 
involvement; moreover, the differences of methods applied to measure tumour size in SLN represent a 
major impediment to the comparison between the different studies [12], [13], [14], [15], [16], [17], [18], 
[19], [20] and [21]. The EORTC Melanoma Group suggested to stratify tumour burden into three categories 
namely <0.1 mm, 0.1–1.0 mm or >1.0 mm [29]. Other authors suggested different cut-off point in terms of 
size measures: more or less than 2 mm according to Roka et al. [8] or more or less than 1 mm according to 
Dewar [30]. The latter author found that, a part from the tumour size, also the micro-anatomic location of 
SLN metastases was predictive for NSLN involvement suggesting that patients with only sub-capsular 
deposits could be spared from CLND. 
The main result of our study is that we were able to identify three variables significantly associated 
with a higher risk of NSLN metastases (Breslow thickness, ulceration, SLN micro-/macro-metastatic 
pattern). The same variables were found to play an unfavourable prognostic role on OS. Several papers 
have already showed that the pattern of SLN involvement [7], [17], [18] and [19] as well as the number of 
positive SLNs [19] were predictive on the NSLN involvement, as the Starz classification that the same author 
utilized in the classification of 2001 [31] and 2004 [17]. That revision is relatively simple to measure 
because needs only of a micrometer ocular and its usefulness have also been confirmed by recent works 
[32]. In our experience, the number of positive SLNs was not associated to an increasing NSLN involvement, 
whilst the prognostic relevance of Starz classification was ascertained in univariate but not confirmed in 
multivariate logistic regression analysis. The predictive value of Breslow thickness on NSLN involvement has 
been found in some previous papers, but not confirmed by others [10], [13], [14], [15], [20], [31] and [33]; 
the same happens for ulceration, thus confirming a great deal of variability which limits the drawing of 
definite conclusions. Some studies suggested also to consider the association of two or more variables. In 
fact Frankel et al. [19] utilized the relation between percentage of the surface area of the metastases on 
SLN and Breslow thickness while Reeves et al. [20] utilized S/U score (size of metastases on SLN/ulceration). 
As a second step in our study, we showed that the likelihood of NSLN involvement increased in our 
patients along with the number of adverse indicators (Breslow thickness > 2 mm; ulceration; macro-
metastatic pattern of SLN invasion) from 4.3% in patients without adverse features up to 55.9% when two 
or three adverse factors were present. Therefore, our results do suggest that in selected cases with 
significant co-morbidities and/or elderly age, the finding of no adverse prognostic indicators could be useful 
in identifying patients not to treat by regional node dissection. In these patients, a strict follow-up program 
with radiological work-ups such as nodal ultrasound and/or positron emission tomography plus computed 
tomography (PET/CT) could be applied. Ultrasonography associated with Doppler evaluation is of choice in 
the monitoring of the regional basin, in as much as its sensibility in the detection of occult nodal metastases 
is approaching 90%; ultrasound utility is now being evaluated by the MSLT-II trial. On the other hand, 
PET/TC has a diagnostic accuracy superior to that of TC alone in the early detection of visceral metastases 
whilst its sensitivity in the evaluation of node metastases appears to be lower due to the fact that tumour 
deposits can be far below its detection threshold [34], [35] and [36]. 
 
 
 
 
 
 Figure 1. Overall Survival (OS) according to prognostic indicators: a) Breslow thickness > 2 mm (p = 0.0069); 
b) ulceration (p = 0.0495) c) SLN micro-/macro-metastatic pattern (p = 0.0190); d) number of adverse 
prognostic indicators (0,1,2 or more; p < 0.001). 
 
 
Another controversial point is the impact of SLN features on OS. In comparison with the high 
literature coverage of NSLN involvement predictive factors, few data are reported on this latter topic. 
Previous studies indicated that the dimensions of nodal tumour deposits could be significant predictors [37] 
and [38]. Roka et al. [8] reported an SLN tumour size >2 mm, presence of NSLN involvement and Breslow 
thickness to be associated with different recurrence-free and disease-specific survival and confirmed the 
prognostic relevance of the S/U score proposed by Reeves et al. [20] In another paper, the presence of 
micro-metastatic tumour deposits in SLN was associated to a significantly better prognosis with respect to 
macrometastases [9]. A recent German study [39] found the greatest dimension of the largest tumour cell 
deposit, the tumour penetrative depth and capsular involvement as independent parameters for relapse-
free and overall survival. The invasion depth (Starz classification) [17] was also found by previous studies to 
best predict overall survival [16], [18] and [40]. In our experience, however, Starz classification failed to 
disclose a significant association with a different clinical course, as well as the number of positive SLNs. It is 
interesting to note that our study found that the same variables associated with a higher likelihood of NSLN 
involvement carried also a prognostic impact on OS. However, it could be hypothesized that these variables 
may not have a prognostic impact on their own but only depending on their association with NSLN 
involvement. To this aim, we separated our patients according to NSLN involvement into two groups 
(presence or absence of melanoma cells) and we analysed in both groups the OS of patients according to 
the Breslow thickness, ulceration and micro-/macro-metastatic pattern (data not shown). The number of 
adverse prognostic indicators maintained a statistically significant association with the disease course not 
only in patients without NSLN involvement (p = 0.001) but also in patients harbouring NSLN metastases (p = 
0.05) even with a lesser degree of evidence. These results suggest therefore that the evaluation of the 
factors emerged from our study maintain a potential prognostic significance to be considered together with 
the well-known significance of NSLN score. 
In conclusion, this study suggests a clinically useful and an easily applicable means of identifying 
melanoma patients with a potentially more unfavourable disease course on the basis of the concomitant 
evaluation of Breslow thickness, ulceration and SLN micro/macro-metastatic pattern. The presence of at 
least one of these adverse factors identify patients in whom CLND is mandatory; these patients should be 
included thereafter in a more strict follow-up program with more frequent clinical visits and radiological 
procedures given the unfavourable prognosis. On the other hand, the finding of no adverse indicators 
identify patients who could be spared from CLND in the presence of significant co-morbidities or elderly 
age. The relatively low number of patients included in this single centre study and the absence of a control 
group for validation, limit the achievement of more insights into this controversial topic for which the 
conclusions of the MSLT-II trial are awaited. 
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